Bio-Rad Laboratories, Inc. (BIO) — ESG & Values Scores

Environment story

Bio-Rad has disclosed limited environmental metrics and provides no quantified Scope 1, 2, or 3 emissions data in available filings. No net-zero target year is disclosed. The company acknowledges sustainability goals and ongoing investment in compliance with evolving climate regulations, but implementation specifics and decarbonization infrastructure investments are not detailed. Environmental controversies are minimal in disclosed materials; however, the company operates manufacturing and distribution facilities globally and is subject to environmental laws covering transportation, emissions, water discharges, and hazardous waste handling. No material environmental fines or protests are documented in the 10-K. The lack of transparent emissions reporting, absence of a credible net-zero target, and undisclosed scope 3 emissions result in a below-median environmental score reflecting greenwashing risk and compliance-posture-only positioning.

Criticisms on file

Lack of quantified Scope 1, 2, and 3 emissions disclosure; no net-zero target year disclosed.
Source: BIO 10-K 2025, Item 1A Risk Factors and MD&A; no sustainability report provided.
Acknowledgment of potential future environmental fines and liabilities related to spills, disposals, or releases of hazardous substances, but no current material incidents disclosed.
Source: BIO 10-K 2025, Item 1A Risk Factors: 'Environmental, health and safety regulations and enforcement proceedings may negatively impact our business.'

Disclosed initiatives

Sustainability Goals Announced

Company has announced certain sustainability goals requiring ongoing investment and operational changes.

Unspecified; achievement is uncertain and may not meet stakeholder expectations.
Environmental Compliance Programs

Compliance with federal, state, local and foreign environmental laws governing transportation, emissions, water discharges, and hazardous waste handling.

Ongoing operational cost; no quantified emissions reductions disclosed.

Social story

Bio-Rad provides minimal quantitative diversity and compensation data in the 10-K. No CEO-to-median-worker pay ratio, workforce diversity percentages, or leadership diversity metrics are disclosed. No union suppression activities, major strikes, or documented labor violations within the past 24 months are reported. The company acknowledges global labor relations laws, FCPA compliance, and the importance of attracting and retaining key personnel, but does not disclose formal DEI programs, supplier-diversity initiatives, or human-rights audits. Supply-chain ethics policies for high-risk geographies (e.g., conflict minerals, cobalt) are not detailed. Recent organizational restructurings (2023, 2024, 2025) are disclosed as potential sources of labor unrest and workforce attrition risk. Overall, the company presents a neutral labor-relations posture with documented oversight of international compliance but lacks transparency on diversity, pay equity, and supply-chain human-rights due diligence.

Criticisms on file

Organizational restructurings in 2023, 2024, and 2025 pose risks of labor unrest, workforce attrition, employee morale reduction, and business disruption.
Source: BIO 10-K 2025, Item 1A Risk Factors: 'Recent and planned changes to our organizational structure could negatively impact our business.'
No disclosed diversity metrics, pay-equity policies, or formal DEI programs; lack of transparency on leadership and workforce representation.
Source: BIO 10-K 2025; absence of EEO-1 disclosures, diversity reports, or human-capital metrics in MD&A and risk factors.
Supply-chain ethics and human-rights audit procedures not disclosed; company operates globally and acquires materials from numerous countries with varying labor-standards compliance.
Source: BIO 10-K 2025, Item 1A Risk Factors: 'International operations expose us to additional costs and legal and regulatory risks'; no conflict-minerals or supply-chain audit policy detailed.

Disclosed initiatives

Global Compliance with Labor Relations Laws

Company acknowledges complex foreign and U.S. labor relations laws and the need for compliance through policies, procedures and internal controls.

Administrative overhead; no quantified workforce benefits or improvements disclosed.
Talent Attraction and Retention Programs

Company recognizes need for competitive compensation and benefits to attract and retain qualified scientific, technical and specialized personnel.

Competitive positioning; specific diversity targets, pay-equity commitments, or outcomes not disclosed.
International Compliance and FCPA Oversight

Company implements policies and procedures to manage FCPA, UK Bribery Act, and foreign corruption risks across dispersed international sales organization.

Compliance cost; reduces reputational risk in high-corruption-risk jurisdictions.

Governance story

Bio-Rad operates under a dual-class share structure with Class A (one-tenth vote) and Class B (one vote) shares, resulting in Schwartz family control of a majority of board seats and voting power. This represents a material governance weakness, as the controlling family can elect >50% of directors and effect fundamental business changes independent of minority shareholders. Board independence percentage is not disclosed in the 10-K. No material antitrust, consumer-safety, or financial-fraud regulatory proceedings are disclosed. Lobbying expenditures and PAC contributions are not quantified or disclosed. The company maintains a Delaware forum-selection bylaw provision restricting derivative and internal-affairs disputes to Delaware courts, which may increase shareholder litigation costs. No evidence of active lobbying to weaken climate regulation or consumer-protection statutes is disclosed. The company has experienced material weaknesses in internal control over financial reporting in the past (acknowledged in risk factors), raising governance-control concerns. Goodwill impairment testing is conducted annually, though material judgments and estimation uncertainty are present. Overall, the dual-class structure and lack of board-independence transparency represent the primary governance deficiencies.

Criticisms on file

Dual-class share structure with Schwartz family majority voting control; family can elect >50% of directors and effect fundamental business changes without minority-shareholder consent.
Source: BIO 10-K 2025, Item 1A Risk Factors: 'A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.' Directors elected separately by class; Class A holders elect 25% of board; Class B holders elect remaining directors.
Delaware forum-selection bylaw provision may increase costs to shareholders bringing derivative actions or internal-affairs disputes; may discourage litigation.
Source: BIO 10-K 2025, Item 1A Risk Factors: 'The forum selection provision in our bylaws could increase costs to bring a claim, discourage claims or limit the ability of the Company's stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable.'
Material weaknesses in internal control over financial reporting have occurred in the past; risk of recurrence and material misstatements acknowledged.
Source: BIO 10-K 2025, Item 1A Risk Factors: 'Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements.'
Significant goodwill impairment charges in 2025 ($81.7M Dropworks, $91.1M Curiosity net) resulting from delayed technology completion and revised revenue forecasts; reflects acquisition-integration risk and valuation uncertainty.
Source: BIO 10-K 2025, MD&A: 'Impairment of purchased intangibles and related items, net' section.
Board independence percentage not disclosed; dual-class voting structure limits minority shareholder influence on board composition and governance decisions.
Source: BIO 10-K 2025; board composition and independence metrics not provided in proxy or 10-K disclosures reviewed.

Disclosed initiatives

Internal Control Over Financial Reporting

Company maintains disclosure controls, procedures, and internal control framework required by Sarbanes-Oxley Act Section 404; annual management evaluation and auditor attestation required.

Regulatory compliance; material weaknesses have occurred in the past and could recur, impacting investor confidence.
Goodwill Impairment Testing

Annual goodwill impairment analysis conducted in Q4 or more frequently if impairment indicators exist. Quantitative testing performed at reporting-unit level using income approach (discounted cash flow).

Financial statement accuracy; significant management judgment required; impairment charges (e.g., $81.7M Dropworks, $91.1M Curiosity net impairment in 2025) can materially impact earnings.
Tax Compliance and Uncertain Tax Position Management

Company records liabilities for unrecognized tax benefits; routinely undergoes income-tax audits by U.S. federal, state, and foreign authorities; assesses adequacy of tax provisions.

Ongoing audit risk; potential for material adjustments if uncertain tax positions resolved unfavorably.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Bio-Rad Laboratories, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Bio-Rad Laboratories, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)